ALIMERA SCIENCES, INC. (NASDAQ:ALIM) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

As previously disclosed, on December 31, 2019, Alimera Sciences, Inc. (“Alimera”) entered into a $45.0 million Loan and Security Agreement (the “Loan Agreement”) with Solar Capital Ltd. (“Solar Capital”), as Collateral Agent, and the parties signing the Loan Agreement from time to time as Lenders, including Solar Capital in its capacity as a Lender, and borrowed $42.5 million. Under the Loan Agreement, Alimera had the option to borrow an additional $2.5 million (the “Term B Loan”) if it achieved $30.0 million in revenue for any trailing six-month period ending on or before November 30, 2020 from sales of ILUVIEN® in the ordinary course of business to third party customers. Alimera borrowed the Term B Loan on February 21, 2020, having qualified for the borrowing based on revenue for the six-month period ending December 31, 2019. The Term B Loan brings Alimera’s total borrowings under the Loan Agreement to the maximum $45.0 million available.

Alimera expects to use the proceeds from the Term B Loan to provide additional working capital for general corporate purposes.

The summary of the terms of the Loan Agreement set forth in Alimera’s Current Report on Form 8-K dated December 31, 2019 and filed with the SEC on January 6, 2020 is hereby incorporated by reference into this Current Report on Form 8-K (this “Report”).

Item 7.01. Regulation FD.

Alimera issued a press release regarding the Term B Loan on the date of this Report. The full text of the press release is furnished as Exhibit 99.1 to this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits